Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt No Debt
XNPT's Cash to Debt is ranked higher than
92% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. XNPT: No Debt )
XNPT' s 10-Year Cash to Debt Range
Min: 8.78   Max: No Debt
Current: No Debt

Equity to Asset 0.68
XNPT's Equity to Asset is ranked higher than
73% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. XNPT: 0.68 )
XNPT' s 10-Year Equity to Asset Range
Min: -1.61   Max: 0.82
Current: 0.68

-1.61
0.82
F-Score: 1
Z-Score: -6.12
M-Score: -0.48
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -1076.95
XNPT's Operating margin (%) is ranked higher than
54% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. XNPT: -1076.95 )
XNPT' s 10-Year Operating margin (%) Range
Min: -5504.8   Max: 18.25
Current: -1076.95

-5504.8
18.25
Net-margin (%) -1080.15
XNPT's Net-margin (%) is ranked higher than
53% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. XNPT: -1080.15 )
XNPT' s 10-Year Net-margin (%) Range
Min: -4876   Max: 24.77
Current: -1080.15

-4876
24.77
ROE (%) -159.95
XNPT's ROE (%) is ranked higher than
50% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. XNPT: -159.95 )
XNPT' s 10-Year ROE (%) Range
Min: -159.95   Max: 22.46
Current: -159.95

-159.95
22.46
ROA (%) -109.35
XNPT's ROA (%) is ranked higher than
51% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. XNPT: -109.35 )
XNPT' s 10-Year ROA (%) Range
Min: -109.35   Max: 16.31
Current: -109.35

-109.35
16.31
ROC (Joel Greenblatt) (%) -3355.33
XNPT's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. XNPT: -3355.33 )
XNPT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3355.33   Max: 305.89
Current: -3355.33

-3355.33
305.89
Revenue Growth (%) 23.60
XNPT's Revenue Growth (%) is ranked higher than
91% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. XNPT: 23.60 )
XNPT' s 10-Year Revenue Growth (%) Range
Min: -72.6   Max: 126.3
Current: 23.6

-72.6
126.3
EBITDA Growth (%) -11.70
XNPT's EBITDA Growth (%) is ranked higher than
72% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. XNPT: -11.70 )
XNPT' s 10-Year EBITDA Growth (%) Range
Min: -54.3   Max: -7.9
Current: -11.7

-54.3
-7.9
EPS Growth (%) -12.30
XNPT's EPS Growth (%) is ranked higher than
75% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. XNPT: -12.30 )
XNPT' s 10-Year EPS Growth (%) Range
Min: -52.3   Max: -7.4
Current: -12.3

-52.3
-7.4
» XNPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

XNPT Guru Trades in Q1 2013

Jim Simons 318,300 sh (New)
Steven Cohen 1,200 sh (New)
PRIMECAP Management 127,000 sh (unchged)
» More
Q2 2013

XNPT Guru Trades in Q2 2013

Paul Tudor Jones 53,300 sh (New)
PRIMECAP Management 128,000 sh (+0.79%)
Steven Cohen Sold Out
Jim Simons 110,600 sh (-65.25%)
» More
Q3 2013

XNPT Guru Trades in Q3 2013

PRIMECAP Management 128,000 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
Q4 2013

XNPT Guru Trades in Q4 2013

Jim Simons 59,312 sh (New)
PRIMECAP Management 128,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with XNPT

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2012-06-30 New Buy$4.08 - $6.15 $ 4.2-19%125000
George Soros 2011-12-31 Sold Out 0.0016%$3.57 - $6.34 $ 4.2-16%0
George Soros 2011-09-30 Reduce -38.17%$5.95 - $7.72 $ 4.2-40%16200
George Soros 2011-06-30 New Buy$6.05 - $9.31 $ 4.2-44%26200
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.70
XNPT's P/B is ranked higher than
70% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. XNPT: 3.70 )
XNPT' s 10-Year P/B Range
Min: 1.71   Max: 13.19
Current: 3.7

1.71
13.19
P/S 25.10
XNPT's P/S is ranked lower than
67% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. XNPT: 25.10 )
XNPT' s 10-Year P/S Range
Min: 2.65   Max: 111.17
Current: 25.1

2.65
111.17
EV-to-EBIT 25.60
XNPT's EV-to-EBIT is ranked lower than
55% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. XNPT: 25.60 )
XNPT' s 10-Year EV-to-EBIT Range
Min: 50.9   Max: 9027.3
Current: 25.6

50.9
9027.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.90
XNPT's Price/Net Cash is ranked higher than
73% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. XNPT: 5.90 )
XNPT' s 10-Year Price/Net Cash Range
Min: 2.06   Max: 12.42
Current: 5.9

2.06
12.42
Price/Net Current Asset Value 5.70
XNPT's Price/Net Current Asset Value is ranked higher than
72% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. XNPT: 5.70 )
XNPT' s 10-Year Price/Net Current Asset Value Range
Min: 2.06   Max: 12.31
Current: 5.7

2.06
12.31
Price/Tangible Book 3.80
XNPT's Price/Tangible Book is ranked higher than
73% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. XNPT: 3.80 )
XNPT' s 10-Year Price/Tangible Book Range
Min: 1.8   Max: 11.18
Current: 3.8

1.8
11.18
Price/Median PS Value 1.80
XNPT's Price/Median PS Value is ranked lower than
58% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. XNPT: 1.80 )
XNPT' s 10-Year Price/Median PS Value Range
Min: 0.22   Max: 6.66
Current: 1.8

0.22
6.66
Earnings Yield (Greenblatt) 3.90
XNPT's Earnings Yield (Greenblatt) is ranked higher than
57% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. XNPT: 3.90 )
XNPT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.3   Max: 4
Current: 3.9

1.3
4
Forward Rate of Return (Yacktman) -47.75
XNPT's Forward Rate of Return (Yacktman) is ranked higher than
61% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. XNPT: -47.75 )
XNPT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -22.2   Max: -16.3
Current: -47.75

-22.2
-16.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:LMW.Germany
XenoPort, Inc., is a Delaware corporation was incorporated on May 19, 1999. The Company is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates with an initial focus on neurological disorders. Its product candidates are prodrugs that are typically created by modifying the chemical structure of currently marketed drugs, referred to as parent drugs, and are designed to correct limitations in the oral absorption, distribution and/or metabolism of the parent drug. Its marketed product and each of its product candidates are orally available, patented or patentable molecules that address potential markets with clear unmet medical needs. Its marketed product is approved in the United States, where it is known as Horizant (gabapentin enacarbil) Extended-Release Tablets, and in Japan, where it is known as Regnite (gabapentin enacarbil) Extended-Release Tablets. Horizant has been approved by the U.S. Food and Drug Administration, or FDA, for the treatment of moderate-to-severe primary restless legs syndrome, or RLS, in adults and for the management of postherpetic neuralgia, or PHN, in adults. Restless legs syndrome, also known as Willis-Ekbom Disease, is a neurological disorder characterized by an urge to move the legs, usually caused or accompanied by uncomfortable and unpleasant sensations in the legs. PHN is a neuropathic (nerve) pain syndrome that can follow the healing of an outbreak of herpes zoster, commonly known as shingles. Regnite has been approved by the Japanese Ministry of Health, Labor and Welfare, or MHLW, as a treatment for patients with RLS. Gabapentin enacarbil is licensed to Astellas Pharma Inc. in Japan and five other Asian countries. It has three product candidates in clinical development. Its product candidate, arbaclofen placarbil, or AP, is a potential treatment for patients with spasticity. It is conducting a pivotal Phase 3 clinical trial under a Special Protocol Assessment, or SPA, with the FDA for AP as a potential treatment for spasticity in patients with multiple sclerosis, or MS. Its second product candidate, XP21279, is a potential treatment for patients with advanced idiopathic Parkinson's disease. In 2011, it completed a Phase 2 clinical trial of XP21279/carbidopa compared to patient-optimized doses of Sinemet (levodopa/carbidopa) in patients with Parkinson's disease who experience motor fluctuations. It is evaluating its third product candidate, XP23829, in Phase 1 studies with healthy subjects to determine its safety and pharmacokinetic profile. GSK holds commercialization rights for Horizant in the United States during a transition period ending on April 30, 2013. The Company face competition from established pharmaceutical and biotechnology companies, including generic competitors, as well as from academic institutions, government agencies and private and public research institutions. The Company is subject to regulation by regi

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide